SGMO Shoots Up On GILD Deal, MESO Has A Blast, Mark Your Calendar For GTHX

G1 Therapeutics Inc. (GTHX) gained 14.52% on Thursday. The Company has 3 drug candidates in its pipeline namely, Trilaciclib, G1T38 and G1T48. Topline data from a phase 2a trial of chemotherapy with or without Trilaciclib in first-line SCLC is expected to be reported in March 2018.

from RTT - Biotech http://ift.tt/2CDabC4
via IFTTT